Dipharma’s Novel Approach to Nitrosamine Detection in APIs
Dipharma reports a new analytical approach that combines 15N‑enriched nitrosating reagents with 15N NMR readout to selectively detect and...
eClinical Tech News
Hutchmed Highlights New Clinical Data for 2025 ESMO & ASH
HUTCHMED will take a multi-asset slate to ESMO Asia and ASH in early December, flagging new and updated readouts...
Xenon to Present New Azetukalner Epilepsy Data at AES 2025
A ≥48-month interim analysis from Xenon’s ongoing seven-year X-TOLE open-label extension will be featured at AES 2025, focusing on...
Scilex Holding Completes Equity Financing in Datavault AI
Scilex has exercised a pre-funded warrant for 263,914,094 shares of Datavault AI, a stake valued at approximately $583.3 million...
Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025
No new efficacy numbers were disclosed, but Celcuity will present updated subgroup and safety results from the randomized Phase...
FibroBiologics Announces Complete Payoff of Outstanding Debt
FibroBiologics has repaid all amounts outstanding under its Yorkville-issued convertible promissory notes, removing the prospect of further conversions into...
Tangram Announces New Phase 1/2 Trial for MASH Candidate
Tangram Therapeutics has submitted a Clinical Trial Application to the UK MHRA to begin a Phase 1/2 study of...
Hope for ALS: Tiziana’s Nasal Trial Enters Healey Program
Tiziana Life SciencesLife Sciences’ intranasal anti-CD3 antibody, foralumab, has been accepted into the ALS MyMatch Program at the Healey...
Kymera Launches Phase 2b Trial for New Atopic Dermatitis Drug
Kymera has begun dosing in BROADEN2, a 16-week, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in moderate to...
New ENIGMAC Data Reveals Macrophage Role in Fibrotic Disease
Macomics has validated its ENIGMAC macrophage discovery platform in antifibrotic biology, completing pooled and arrayed CRISPR-based gene modulation screens...